As to the issue of drug approval, ______.
A．to judge whether a drug is safe enough should rely on objective measures
B．drug companies usually study for years to prove the safety and effectiveness of a drug
C．drug companies prefer surrogate endpoints in the process of drug approval because F.D.A.encourages them to do so
D．drug companies rely heavily on surrogated endpoints because this way of measurement takes less time and money